Exelixis, Inc. (NASDAQ: EXEL) is a Healthcare company (Biotechnology) with a market capitalization of $17.3B. The Maz Rating grades it against the other companies in its sector.
Exelixis, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $69.00, Exelixis, Inc. trades at 20.0x trailing earnings, 6.9x sales and 9.3x book value, with an EV/EBITDA of 16.0. Over the last twelve months it generated about $2.5B of revenue and $867M of net income. It runs a gross margin of 96.3%, an operating margin of 40.2% and a net margin of 35.5%. It shows return on equity of 45.5%, return on invested capital of 39.6% and a free cash flow yield of 6.6%. On the balance sheet: a debt-to-equity ratio of 0.09 and a current ratio of 3.21. Over the past 52 weeks the share price ranged from $39.71 to $73.69, with a beta of 0.42.
Exelixis, Inc. does not currently pay a dividend.
33 Wall Street analyst ratings cover the stock: 15 Buy and 18 Hold, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of October 2026, Exelixis, Inc. (EXEL) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 9.20% / 30% · Interest income / Revenue 2.17% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 5.86% / 33% · Receivables / Mkt Cap (36m) 2.16% / 49% · Interest income / Revenue 2.17% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 5.86% / 33.33% · Receivables / Mkt Cap (24m) 2.16% / 33.33% · Interest income / Revenue 2.17% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.00% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 34.2% / 33.33% · Receivables / Avg Assets (4Q) 12.2% / 33.33% · Interest income / Revenue 2.17% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 35.5% / 33.33% · (Cash+Recv) / Total Assets 48.6% / 33.33% · Interest income / Revenue 2.17% / 5% | Fail |
It depends on the standard you follow. As of October 2026, Exelixis, Inc. (EXEL) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Exelixis, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 2.17% of each dividend: Exelixis, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated October 2, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.